|
1
|
National Cancer Institute, . Common
terminology criteria for adverse events (CTCAE) v5.0. 2017,
https://www.meddra.org/September 5–2018
|
|
2
|
Green MR and Couchman JR: Differences in
human skin between the epidermal growth factor receptor
distribution detected by EGF binding and monoclonal antibody
recognition. J Invest Dermatol. 85:239–245. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lacouture ME: Mechanisms of cutaneous
toxicities to EGFR inhibitors. Nat Rev Cancer. 6:803–812. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rodeck U: Skin toxicity caused by EGFR
antagonists-an autoinflammatory condition triggered by deregulated
IL-1 signaling? J Cell Physiol. 218:32–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Johnston JB, Navaratnam S, Pitz MW,
Maniate JM, Wiechec E, Baust H, Gingerich J, Skliris GP, Murphy LC
and Los M: Targeting the EGFR pathway for cancer therapy. Curr Med
Chem. 13:3483–3492. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fakih M and Vincent M: Adverse events
associated with anti-EGFR therapies for the treatment of metastatic
colorectal cancer. Curr Oncol. 17 (Suppl 1):S18–S30. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Davies BR, Logie A, McKay JS, Martin P,
Steele S, Jenkins R, Cockerill M, Cartlidge S and Smith PD: AZD6244
(ARRY-142886), a potent inhibitor of mitogen-activated protein
kinase/extracellular signal-regulated kinase kinase 1/2 kinases:
Mechanism of action in vivo, pharmacokinetic/pharmacodynamic
relationship, and potential for combination in preclinical. Mol
Cancer Ther. 6:2209–2219. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Haass NK, Sproesser K, Nguyen TK,
Contractor R, Medina CA, Nathanson KL, Herlyn M and Smalley KS: The
mitogen-activated protein/extracellular signal-regulated kinase
kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in
melanoma cells and tumor regression when combined with docetaxel.
Clin Cancer Res. 14:230–239. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huynh H, Soo KC, Chow PK and Tran E:
Targeted inhibition of the extracellular signal-regulated kinase
kinase pathway with AZD6244 (ARRY-142886) in the treatment of
hepatocellular carcinoma. Mol Cancer Ther. 6:138–146. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Adjei AA, Cohen RB, Franklin W, Morris C,
Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, et al:
Phase I pharmacokinetic and pharmacodynamic study of the oral,
small-molecule mitogen-activated protein kinase kinase 1/2
inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
J Clin Oncol. 26:2139–2146. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Flaherty KT, Robert C, Hersey P, Nathan P,
Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et
al: Improved survival with MEK inhibition in BRAF-mutated melanoma.
N Engl J Med. 367:107–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Balagula Y, Barth Huston K, Busam KJ,
Lacouture ME, Chapman PB and Myskowski PL: Dermatologic side
effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244,
ARRY-142886). Invest New Drugs. 29:1114–1121. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuske M, Westphal D, Wehner R, Schmitz M,
Beissert S, Praetorius C and Meier F: Immunomodulatory effects of
BRAF and MEK inhibitors: Implications for melanoma therapy.
Pharmacol Res. 136:151–159. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Flaherty KT, Infante JR, Daud A, Gonzalez
R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N,
et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600
mutations. N Engl J Med. 367:1694–1703. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun Y, Liu WZ, Liu T, Feng X, Yang N and
Zhou HF: Signaling pathway of MAPK/ERK in cell proliferation,
differentiation, migration, senescence and apoptosis. J Recept
Signal Transduct Res. 35:600–604. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Curtin JA, Fridlyand J, Kageshita T, Patel
HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, et
al: Distinct sets of genetic alterations in melanoma. N Engl J Med.
353:2135–2147. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hauschild A, Grob JJ, Demidov LV, Jouary
T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr,
Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma:
A multicentre, open-label, phase 3 randomised controlled trial.
Lancet. 380:358–365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al: Improved survival with vemurafenib in melanoma with BRAF V600E
mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Macdonald JB, Macdonald B, Golitz LE,
LoRusso P and Sekulic A: Cutaneous adverse effects of targeted
therapies: Part I: Inhibitors of the cellular membrane. J Am Acad
Dermatol. 72:203–218. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hermanson M, Funa K, Hartman M,
Claesson-Welsh L, Heldin CH, Westermark B and Nistér M:
Platelet-derived growth factor and its receptors in human glioma
tissue: Expression of messenger RNA and protein suggests the
presence of autocrine and paracrine loops. Cancer Res.
52:3213–3219. 1992.PubMed/NCBI
|
|
21
|
Seymour L, Dajee D and Bezwoda WR: Tissue
platelet derived-growth factor (PDGF) predicts for shortened
survival and treatment failure in advanced breast cancer. Breast
Cancer Res Treat. 26:247–252. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Smits A, Funa K, Vassbotn FS,
Beausang-Linder M, af Ekenstam F, Heldin CH, Westermark B and
Nistér M: Expression of platelet-derived growth factor and its
receptors in proliferative disorders of fibroblastic origin. Am J
Pathol. 140:639–648. 1992.PubMed/NCBI
|
|
23
|
Liu KW, Hu B and Cheng SY:
Platelet-derived growth factor signaling in human malignancies.
Chin J Cancer. 30:581–584. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
O'Brien SG, Guilhot F, Larson RA, Gathmann
I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A,
Hughes T, et al: Imatinib compared with interferon and low-dose
cytarabine for newly diagnosed chronic-phase chronic myeloid
leukemia. N Engl J Med. 348:994–1004. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Das D, Ganguly S, Deb AR and Aich RK:
Neoodjuvant imatinib mesylate for advanced primary and
metastactic/recurrent gastro-intestinal stromal tumour (GIST). J
Indian Med Assoc. 111:21–23. 2013.PubMed/NCBI
|
|
26
|
Liu-Dumlao T, Kantarjian H, Thomas DA,
O'Brien S and Ravandi F: Philadelphia-positive acute lymphoblastic
leukemia: Current treatment options. Curr Oncol Rep. 14:387–394.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pardanani A: Systemic mastocytosis in
adults: 2015 update on diagnosis, risk stratification, and
management. Am J Hematol. 90:250–262. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ugurel S, Mentzel T, Utikal J, Helmbold P,
Mohr P, Pföhler C, Schiller M, Hauschild A, Hein R, Kämpgen E, et
al: Neoadjuvant imatinib in advanced primary or locally recurrent
dermatofibrosarcoma protuberans: A multicenter phase II DeCOG trial
with long-term follow-up. Clin Cancer Res. 20:499–510. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hodi FS, Corless CL, Giobbie-Hurder A,
Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R,
Weber JS, Gajewski TF, et al: Imatinib for melanomas harboring
mutationally activated or amplified KIT arising on mucosal, acral,
and chronically sun-damaged skin. J Clin Oncol. 31:3182–3190. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Koon HB, Krown SE, Lee JY, Honda K,
Rapisuwon S, Wang Z, Aboulafia D, Reid EG, Rudek MA, Dezube BJ and
Noy A: Phase II trial of imatinib in AIDS-associated Kaposi's
sarcoma: AIDS malignancy consortium protocol 042. J Clin Oncol.
32:402–408. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu FT, Li NG, Zhang YM, Xie WC, Yang SP,
Lu T and Shi ZH: Recent advance in the development of novel,
selective and potent FGFR inhibitors. Eur J Med Chem.
186:1118842020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
de Almeida Carvalho LM, de Oliveira Sapori
Avelar S, Haslam A, Gill J and Prasad V: Estimation of percentage
of patients with fibroblast growth factor receptor alterations
eligible for off-label use of erdafitinib. JAMA Netw Open.
2:e19160912019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Katoh M: FGFR inhibitors: Effects on
cancer cells, tumor microenvironment and whole-body homeostasis
(Review). Int J Mol Med. 38:3–15. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Helsten T, Elkin S, Arthur E, Tomson BN,
Carter J and Kurzrock R: The FGFR landscape in cancer: Analysis of
4,853 tumors by next-generation sequencing. Clin Cancer Res.
22:259–267. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Arudra K, Patel R, Tetzlaff MT, Hymes S,
Subbiah V, Meric-Bernstam F, Torres-Cabala C, Aung PP, Nagarajan P,
Diab A, et al: Calcinosis cutis dermatologic toxicity associated
with fibroblast growth factor receptor inhibitor for the treatment
of Wilms tumor. J Cutan Pathol. 45:786–790. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Carr DR, Pootrakul L, Chen HZ and Chung
CG: Metastatic calcinosis cutis associated with a selective FGFR
inhibitor. JAMA Dermatol. 155:122–123. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Miyanaga A, Shimizu K, Noro R, Seike M,
Kitamura K, Kosaihira S, Minegishi Y, Shukuya T, Yoshimura A,
Kawamoto M, et al: Activity of EGFR-tyrosine kinase and ALK
inhibitors for EML4-ALK-rearranged non-small-cell lung cancer
harbored coexisting EGFR mutation. BMC Cancer. 13:2622013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hou H, Sun D, Liu K, Jiang M, Liu D, Zhu
J, Zhou N, Cong J and Zhang X: The safety and serious adverse
events of approved ALK inhibitors in malignancies: A meta-analysis.
Cancer Manag Res. 11:4109–4118. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sawamura S, Kajihara I, Ichihara A,
Fukushima S, Jinnin M, Yamaguchi E, Kohrogi H and Ihn H:
Crizotinib-associated erythema multiforme in a lung cancer patient.
Drug Discov Ther. 9:142–143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang S, Wu L, Li X, Huang J, Zhong J and
Chen X: Crizotinib-associated toxic epidermal necrolysis in an
ALK-positive advanced NSCLC patient. Mol Clin Oncol. 8:457–459.
2018.PubMed/NCBI
|
|
41
|
Autier J, Escudier B, Wechsler J, Spatz A
and Robert C: Prospective study of the cutaneous adverse effects of
sorafenib, a novel multikinase inhibitor. Arch Dermatol.
144:886–892. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kong HH and Turner ML: Array of cutaneous
adverse effects associated with sorafenib. J Am Acad Dermatol.
61:360–361. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Robert C, Sibaud V, Mateus C and Cherpelis
BS: Advances in the management of cutaneous toxicities of targeted
therapies. Semin Oncol. 39:227–240. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hurwitz HI, Dowlati A, Saini S, Savage S,
Suttle AB, Gibson DM, Hodge JP, Merkle EM and Pandite L: Phase I
trial of pazopanib in patients with advanced cancer. Clin Cancer
Res. 15:4220–4227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hutson TE, Davis ID, Machiels JP, De Souza
PL, Rottey S, Hong BF, Epstein RJ, Baker KL, McCann L, Crofts T, et
al: Efficacy and safety of pazopanib in patients with metastatic
renal cell carcinoma. J Clin Oncol. 28:475–480. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sternberg CN, Davis ID, Mardiak J,
Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA,
Kavina A, et al: Pazopanib in locally advanced or metastatic renal
cell carcinoma: Results of a randomized phase III trial. J Clin
Oncol. 28:1061–1068. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hartmann JT and Kanz L: Sunitinib and
periodic hair depigmentation due to temporary c-KIT inhibition.
Arch Dermatol. 144:1525–1526. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Robert C, Spatz A, Faivre S, Armand JP and
Raymond E: Tyrosine kinase inhibition and grey hair. Lancet.
361:10562003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Coleman EL, Cowper SE, Stein SM and
Leventhal JS: Erythema nodosum-like Eruption in the setting of
sorafenib therapy. JAMA Dermatol. 154:369–370. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ollech A, Stemmer SM, Merims S, Lotem M,
Popovtzer A, Hendler D, Hodak E, Didkovsky E and Amitay-Laish I:
Widespread morbilliform rash due to sorafenib or vemurafenib
treatment for advanced cancer; experience of a tertiary
dermato-oncology clinic. Int J Dermatol. 55:473–478. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Choi MK, Woo HY, Heo J, Cho M, Kim GH,
Song GA and Kim MB: Toxic epidermal necrolysis associated with
sorafenib and tosufloxacin in a patient with hepatocellular
carcinoma. Ann Dermatol. 23 (Suppl 3):S404–S407. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ikeda M, Fujita T, Amoh Y, Mii S,
Matsumoto K and Iwamura M: Stevens-Johnson syndrome induced by
sorafenib for metastatic renal cell carcinoma. Urol Int.
91:482–483. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yoon J, Oh CW and Kim CY: Stevens-johnson
syndrome induced by vandetanib. Ann Dermatol. 23 (Suppl
3):S343–S345. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Pickert A, Hughes M and Wells M:
Chloracne-like drug eruption associated with sorafenib. J Drugs
Dermatol. 10:1331–1334. 2011.PubMed/NCBI
|
|
56
|
Kim DK and Lee SW, Nam HS, Jeon DS, Park
NR, Nam YH, Lee SK, Baek YH, Han SY and Lee SW: A case of
sorafenib-induced DRESS syndrome in hepatocelluar carcinoma. Korean
J Gastroenterol. 67:337–340. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Epskamp C, Snels DGCTM, Yo GL, Zuetenhorst
HJ and Hamberg P: Bullous fixed drug eruption in a patient with
metastatic renal cell carcinoma induced by iodinated contrast
during pazopanib treatment. Eur J Dermatol. 26:207–208. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
MacGregor JL, Silvers DN, Grossman ME and
Sherman WH: Sorafenib-induced erythema multiforme. J Am Acad
Dermatol. 56:527–528. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Caro-Gutiérrez D, Floristán Muruzábal MU,
Gómez de la Fuente E, Franco AP and López Estebaranz JL:
Photo-induced erythema multiforme associated with vandetanib
administration. J Am Acad Dermatol. 71:e142–e144. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
U.S. Food and Drug Administration, .
Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing
information: Plan B (levonorgestrel). https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125085s0169lbl.pdfAugust
31–2018
|
|
61
|
U.S. Food and Drug Administration, .
Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing
information: CYRAMZA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125477s002lbl.pdfDecember
23–2019
|
|
62
|
Lin WL, Lin WC, Yang JY, Chang YC, Ho HC,
Yang LC, Yang CH, Hung SI and Chung WH: Fatal toxic epidermal
necrolysis associated with cetuximab in a patient with colon
cancer. J Clin Oncol. 26:2779–2780. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Urosevic-Maiwald M, Harr T, French LE and
Dummer R: Stevens-Johnson syndrome and toxic epidermal necrolysis
overlap in a patient receiving cetuximab and radiotherapy for head
and neck cancer. Int J Dermatol. 51:864–867. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Pantano F, Silletta M, Iovieno A, Vincenzi
B, Santini D, Galluzzo S, Bonini S and Tonini G: Stevens-Johnson
syndrome associated with reduced tear production complicating the
use of cetuximab and panitunumab. Int J Colorectal Dis.
24:1247–1248. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Lee SS and Chu PY: Toxic epidermal
necrolysis caused by cetuximab plus minocycline in head and neck
cancer. Am J Otolaryngol. 31:288–290. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Jackman DM, Cioffredi LA, Jacobs L,
Sharmeen F, Morse LK, Lucca J, Plotkin SR, Marcoux PJ, Rabin MS,
Lynch TJ, et al: A phase I trial of high dose gefitinib for
patients with leptomeningeal metastases from non-small cell lung
cancer. Oncotarget. 6:4527–4536. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Huang JJ, Ma SX, Hou X, Wang Z, Zeng YD,
Qin T, Dinglin XX and Chen LK: Toxic epidermal necrolysis related
to AP (pemetrexed plus cisplatin) and gefitinib combination therapy
in a patient with metastatic non-small cell lung cancer. Chin J
Cancer. 34:94–98. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Honda Y, Hattori Y, Katsura S, Terashima
T, Manabe T, Otsuka A and Miyachi Y: Stevens-Johnson syndrome-like
erosive dermatitis possibly related to afatinib. Eur J Dermatol.
26:413–414. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Doesch J, Debus D, Meyer C, Papadopoulos
T, Schultz ES, Ficker JH and Brueckl WM: Afatinib-associated
Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.
Lung Cancer. 95:35–38. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wnorowski AM, de Souza A, Chachoua A and
Cohen DE: The management of EGFR inhibitor adverse events: A case
series and treatment paradigm. Int J Dermatol. 51:223–232. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Lamiaux M, Scalbert C, Lepesant P, Desmedt
E, Templier C, Dziwniel V, Staumont-Sallé D and Mortier L: Severe
skin toxicity with organ damage under the combination of targeted
therapy following immunotherapy in metastatic melanoma. Melanoma
Res. 28:451–457. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Bellón T, Lerma V, González-Valle O,
González Herrada C and de Abajo FJ: Vemurafenib-induced toxic
epidermal necrolysis: Possible cross-reactivity with other
sulfonamide compounds. Br J Dermatol. 174:621–624. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Minor DR, Rodvien R and Kashani-Sabet M:
Successful desensitization in a case of Stevens-Johnson syndrome
due to vemurafenib. Melanoma Res. 22:410–411. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Arenbergerova M, Mrazova I, Horazdovsky J,
Sticova E, Fialova A and Arenberger P: Toxic epidermal necrolysis
induced by vemurafenib after nivolumab failure. J Eur Acad Dermatol
Venereol. 31:e253–e254. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Jeudy G, Dalac-Rat S, Bonniaud B, Hervieu
A, Petrella T, Collet E and Vabres P: Successful switch to
dabrafenib after vemurafenib-induced toxic epidermal necrolysis. Br
J Dermatol. 172:1454–1455. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Lapresta A, Dotor A and González-Herrada
C: Toxic epidermal necrolysis induced by vemurafenib. Actas
Dermosifiliogr. 106:682–683. 2015.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Wantz M, Spanoudi-Kitrimi I, Lasek A,
Lebas D, Quinchon JF and Modiano P: Vemurafenib-induced toxic
epidermal necrolysis. Ann Dermatol Venereol. 141:215–218. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Sinha R, Lecamwasam K, Purshouse K, Reed
J, Middleton MR and Fearfield L: Toxic epidermal necrolysis in a
patient receiving vemurafenib for treatment of metastatic malignant
melanoma. Br J Dermatol. 170:997–999. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Rosen AC, Balagula Y, Raisch DW, Garg V,
Nardone B, Larsen N, Sorrell J, West DP, Anadkat MJ and Lacouture
ME: Life-threatening dermatologic adverse events in oncology.
Anticancer Drugs. 25:225–234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Chen CB, Wu MY, Ng CY, Lu CW, Wu J, Kao
PH, Yang CK, Peng MT, Huang CY, Chang WC, et al: Severe cutaneous
adverse reactions induced by targeted anticancer therapies and
immunotherapies. Cancer Manag Res. 10:1259–1273. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Wenk KS, Pichard DC, Nasabzadeh T, Jang S
and Venna SS: Vemurafenib-Induced DRESS. JAMA Dermatology.
149:12422013. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Munch M, Peuvrel L, Brocard A, Saint Jean
M, Khammari A, Dreno B and Quereux G: Early-onset
vemurafenib-induced DRESS syndrome. Dermatology. 232:126–128. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Gey A, Milpied B, Dutriaux C, Mateus C,
Robert C, Perro G, Taieb A, Ezzedine K and Jouary T: Severe
cutaneous adverse reaction associated with vemurafenib: DRESS, AGEP
or overlap reaction? J Eur Acad Dermatology Venereol. 30:178–179.
2016. View Article : Google Scholar
|
|
84
|
Pinard C, Mignard C, Samain A,
Duval-Modeste AB and Joly P: Successful use of dabrafenib after the
occurrence of drug rash with eosinophilia and systemic symptoms
(DRESS) induced by vemurafenib. JAAD Case Reports. 3:532–533. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Brégeon B, Bernier C, Josselin N, Peuvrel
L, Moigne ML, Saint-Jean M and Quéreux G: Drug reaction with
eosinophilia and systemic symptoms syndrome induced by combination
of vemurafenib and cobimetinib in melanoma: A series of 11 cases. J
Am Acad Dermatol. 80:558–562. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Goldman J, Duval-Modeste AB, Lambert A,
Contentin N, Courville P, Musette P and Joly P: Imatinib-induced
DRESS. Ann Dermatol Venereol. 135:393–396. 2008.(In French).
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Le Nouail P, Viseux V, Chaby G, Billet A,
Denoeux JP and Lok C: Drug reaction with eosinophilia and systemic
symptoms (DRESS) following imatinib therapy. Ann Dermatol Venereol.
133:686–688. 2006.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Kumar M, Mandal PK, Dolai TK and
Bhattacharrya M: Imatinib causing drug rash with eosinophilia and
systemic symptoms: A rare cutaneous reaction. Indian Dermatol
Online J. 5 (Suppl 2):S120–S122. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Saidi W, Lahouel I, Laarif M and Aounallah
A: A new case of imatinib-induced drug reaction with eosinophilia
and systemic symptoms. Indian J Dermatol Venereol Leprol.
83:2242017. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Ben-Ami E, Castells MC, Connell NT,
Rutherford AE and Thornton KA: Imatinib-induced drug reaction with
eosinophilia and systemic symptoms in solid tumors: A patient with
dermatofibrosarcoma protuberans and successful desensitization
management. Anticancer Drugs. 29:919–923. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Vatel O, Aumont C, Mathy V, Petit M,
Feriel J, Sloma I, Bennaceur-Griscelli A and Turhan AG: Drug
reaction with eosinophilia and systemic symptoms (DRESS) induced by
imatinib in chronic myeloid leukemia. Leuk Lymphoma. 58:473–474.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
U.S. Food and Drug Administration, .
Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing
information: Gilotrif. www.fda.gov/medwatchNovember 13–2019
|
|
93
|
Shih HC, Hsiao YP, Wu MF and Yang JH:
Gefitinib-induced acute generalized exanthematous pustulosis in two
patients with advanced non-small-cell lung cancer. Br J Dermatol.
155:1101–1102. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Lakshmi C, Pillai S and Srinivas CR:
Lapatinib-induced acute generalized exanthematous pustulosis.
Indian Dermatol Online J. 1:14–17. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Brouard MC, Prins C, Mach-Pascual S and
Saurat JH: Acute generalized exanthematous pustulosis associated
with STI571 in a patient with chronic myeloid leukemia.
Dermatology. 203:57–59. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Scott AD, Lee M, Kubba F and Chu A: Acute
generalized exanthematous pustulosis (AGEP) secondary to imatinib
in a patient with chronic myeloid leukaemia. Clin Exp Dermatol.
40:926–927. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Schwarz M, Kreuzer KA, Baskaynak G, Dörken
B and le Coutre P: Imatinib-induced acute generalized exanthematous
pustulosis (AGEP) in two patients with chronic myeloid leukemia.
Eur J Haematol. 69:254–256. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Gambillara E, Laffitte E, Widmer N,
Decosterd LA, Duchosal MA, Kovacsovics T and Panizzon RG: Severe
pustular eruption associated with imatinib and voriconazole in a
patient with chronic myeloid leukemia. Dermatology. 211:363–365.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Bastuji-Garin S, Rzany B, Stern RS, Shear
NH, Naldi L and Roujeau JC: Clinical classification of cases of
toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema
multiforme. Arch Dermatol. 129:92–96. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Schwartz RA, McDonough PH and Lee BW:
Toxic epidermal necrolysis: Part I. Introduction, history,
classification, clinical features, systemic manifestations,
etiology, and immunopathogenesis. J Am Acad Dermatol.
69:173.e1–e13, 185–186. 2013. View Article : Google Scholar
|
|
101
|
Rzany B, Hering O, Mockenhaupt M, Schröder
W, Goerttler E, Ring J and Schöpf E: Histopathological and
epidemiological characteristics of patients with erythema
exudativum multiforme major, Stevens-Johnson syndrome and toxic
epidermal necrolysis. Br J Dermatol. 135:6–11. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Harr T and French LE: Stevens-Johnson
syndrome and toxic epidermal necrolysis. Chem Immunol Allergy.
97:149–166. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
U.S. Food and Drug Administration, .
Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing
information: Erbitux. http://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ucm301431.htmNovember
13–2019
|
|
104
|
U.S. Food and Drug Administration, .
Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing
information: Iressa. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206995s003lbl.pdfNovember
13–2019
|
|
105
|
U.S. Food and Drug Administration, .
Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing
information: Tarceva. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdfNovember
13–2019
|
|
106
|
U.S. Food and Drug Administration, .
Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing
information: Vectibix® (panitumumab). https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125147s080lbl.pdfNovember
13–2019
|
|
107
|
U.S. Food and Drug Administration, .
Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing
information: Vizimpro. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdfNovember
13–2019
|
|
108
|
U.S. Food and Drug Administration, .
Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing
information: ZELBORAF (Vemurafenib) Tablet for Oral Use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s012lbl.pdfNovember
13–2019
|
|
109
|
Johnson DB, Wallender EK, Cohen DN,
Likhari SS, Zwerner JP, Powers JG, Shinn L, Kelley MC, Joseph RW
and Sosman JA: Severe cutaneous and neurologic toxicity in melanoma
patients during vemurafenib administration following anti-PD-1
therapy. Cancer Immunol Res. 1:373–377. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Harding JJ, Pulitzer M and Chapman PB:
Vemurafenib sensitivity skin reaction after ipilimumab. N Engl J
Med. 366:866–868. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Mahapatra M, Mishra P and Kumar R:
Imatinib-induced Stevens-Johnson syndrome: Recurrence after
re-challenge with a lower dose. Ann Hematol. 86:537–538. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Pavithran K and Thomas M: Imatinib induced
Stevens-Johnson syndrome: Lack of recurrence following re-challenge
with a lower dose. Indian J Dermatol Venereol Leprol. 71:288–289.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Bois E, Holle LM and Farooq U: Late onset
imatinib-induced Stevens-Johnson syndrome. J Oncol Pharm Pract.
20:476–478. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Sanchez-Gonzalez B, Pascual-Ramirez JC,
Fernandez-Abellan P, Belinchon-Romero I, Rivas C and
Vegara-Aguilera G: Severe skin reaction to imatinib in a case of
Philadelphia-positive acute lymphoblastic leukemia. Blood.
101:24462003. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
U.S. Food and Drug Administration, .
Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing
information: GLEEVEC (Imatinib Mesylate) Tablets Label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdfNovember
13–2019
|
|
116
|
Hsiao LT, Chung HM, Lin JT, Chiou TJ, Liu
JH, Fan FS, Wang WS, Yen CC and Chen PM: Stevens-Johnson syndrome
after treatment with STI571: A case report. Br J Haematol.
117:620–622. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Rule SA, O'Brien SG and Crossman LC:
Managing cutaneous reactions to imatinib therapy. Blood.
100:3434–3435. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Jha P, Himanshu D, Jain N and Singh AK:
Imatinib-induced Stevens-Johnsons syndrome. BMJ Case Rep.
2013:bcr20120079262013. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Nakamoto K, Nagahara H, Noda E, Inoue T,
Maeda K, Ohira G, Amano R, Kubo N, Tanaka H, Muguruma K, et al:
Three cases of giant rectal gastrointestinal stromal tumor. Gan To
Kagaku Ryoho. 38:1984–1986. 2011.(In Japanese). PubMed/NCBI
|
|
120
|
Vidal D, Puig L, Sureda A and Alomar A:
Sti571-induced Stevens-Johnson syndrome. Br J Haematol.
119:274–275. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Schaich M, Schäkel K, Illmer T, Ehninger G
and Bornhäuser M: Severe epidermal necrolysis after treatment with
imatinib and consecutive allogeneic hematopoietic stem cell
transplantation. Ann Hematol. 82:303–304. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Hsieh HJ, Chan ALF and Lin SJ:
Stevens-Johnson syndrome induced by combination of imatinib and
allopurinol. Chemotherapy. 55:197–199. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Severino G, Chillotti C, De Lisa R, Del
Zompo M and Ardau R: Adverse reactions during imatinib and
lansoprazole treatment in gastrointestinal stromal tumors. Ann
Pharmacother. 39:162–164. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
U.S. Food and Drug Administration, .
Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing
information: Tasigna (Nilotinib). https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022068lbl.pdfNovember
13–2019
|
|
125
|
U.S. Food and Drug Administration, .
Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing
information: Sprycel (Dasatinib). https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdfNovember
13–2019
|
|
126
|
U.S. Food and Drug Administration, .
Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing
information: NEXAVAR (Sorafenib) Tablets, for Oral Use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021923s020lbl.pdfNovember
13–2019
|
|
127
|
U.S. Food and Drug Administration, .
Drugs@FDA: FDA-Approved Drugs. Highlights of prescribing
information: Caprelsa (Vandetanib). https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022405s007lbl.pdfNovember
13–2019
|
|
128
|
Szatkowski J and Schwartz RA: Acute
generalized exanthematous pustulosis (AGEP): A review and update. J
Am Acad Dermatol. 73:843–848. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Choudhary S, McLeod M, Torchia D and
Romanelli P: Drug reaction with eosinophilia and systemic symptoms
(DRESS) syndrome. J Clin Aesthet Dermatol. 6:31–37. 2013.PubMed/NCBI
|
|
130
|
Cacoub P, Musette P, Descamps V, Meyer O,
Speirs C, Finzi L and Roujeau JC: The DRESS syndrome: A literature
review. Am J Med. 124:588–597. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Kardaun SH, Sekula P, Valeyrie-Allanore L,
Liss Y, Chu CY, Creamer D, Sidoroff A, Naldi L, Mockenhaupt M and
Roujeau JC; RegiSCAR study group, : Drug reaction with eosinophilia
and systemic symptoms (DRESS): An original multisystem adverse drug
reaction. Results from the prospective RegiSCAR study. Br J
Dermatol. 169:1071–1080. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Ortonne N, Valeyrie-Allanore L,
Bastuji-Garin S, Wechsler J, de Feraudy S, Duong TA, Delfau-Larue
MH, Chosidow O, Wolkenstein P and Roujeau JC: Histopathology of
drug rash with eosinophilia and systemic symptoms syndrome: A
morphological and phenotypical study. Br J Dermatol. 173:50–58.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Funck-Brentano E, Duong TA, Bouvresse S,
Bagot M, Wolkenstein P, Roujeau JC, Chosidow O and
Valeyrie-Allanore L: Therapeutic management of DRESS: A
retrospective study of 38 cases. J Am Acad Dermatol. 72:246–252.
2015. View Article : Google Scholar : PubMed/NCBI
|
